These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

303 related articles for article (PubMed ID: 28817445)

  • 1. The safety of pembrolizumab in metastatic melanoma and rheumatoid arthritis.
    Puri A; Homsi J
    Melanoma Res; 2017 Oct; 27(5):519-523. PubMed ID: 28817445
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pembrolizumab-triggered Uveitis: An Additional Surrogate Marker for Responders in Melanoma Immunotherapy?
    Diem S; Keller F; Rüesch R; Maillard SA; Speiser DE; Dummer R; Siano M; Urner-Bloch U; Goldinger SM; Flatz L
    J Immunother; 2016; 39(9):379-382. PubMed ID: 27662340
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nivolumab and pembrolizumab as immune-modulating monoclonal antibodies targeting the PD-1 receptor to treat melanoma.
    Faghfuri E; Faramarzi MA; Nikfar S; Abdollahi M
    Expert Rev Anticancer Ther; 2015; 15(9):981-93. PubMed ID: 26313415
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intralesional and systemic immunotherapy for metastatic melanoma.
    Luu C; Khushalani NI; Zager JS
    Expert Opin Biol Ther; 2016 Dec; 16(12):1491-1499. PubMed ID: 27602429
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Durable Response of Metastatic Squamous Cell Carcinoma of the Skin to Ipilimumab Immunotherapy.
    Day F; Kumar M; Fenton L; Gedye C
    J Immunother; 2017 Jan; 40(1):36-38. PubMed ID: 27684455
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic factors and outcomes in metastatic uveal melanoma treated with programmed cell death-1 or combined PD-1/cytotoxic T-lymphocyte antigen-4 inhibition.
    Heppt MV; Heinzerling L; Kähler KC; Forschner A; Kirchberger MC; Loquai C; Meissner M; Meier F; Terheyden P; Schell B; Herbst R; Göppner D; Kiecker F; Rafei-Shamsabadi D; Haferkamp S; Huber MA; Utikal J; Ziemer M; Bumeder I; Pfeiffer C; Schäd SG; Schmid-Tannwald C; Tietze JK; Eigentler TK; Berking C
    Eur J Cancer; 2017 Sep; 82():56-65. PubMed ID: 28648699
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of the pharmacokinetics and metabolism of pembrolizumab in the treatment of melanoma.
    Longoria TC; Tewari KS
    Expert Opin Drug Metab Toxicol; 2016 Oct; 12(10):1247-53. PubMed ID: 27485741
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Successful Anti-PD-1 Antibody Treatment in a Metastatic Melanoma Patient With Known Severe Autoimmune Disease.
    Maul LV; Weichenthal M; Kähler KC; Hauschild A
    J Immunother; 2016 May; 39(4):188-90. PubMed ID: 27023060
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety of pembrolizumab for the treatment of melanoma.
    Martin-Liberal J; Kordbacheh T; Larkin J
    Expert Opin Drug Saf; 2015 Jun; 14(6):957-64. PubMed ID: 25927979
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma.
    Ribas A; Hamid O; Daud A; Hodi FS; Wolchok JD; Kefford R; Joshua AM; Patnaik A; Hwu WJ; Weber JS; Gangadhar TC; Hersey P; Dronca R; Joseph RW; Zarour H; Chmielowski B; Lawrence DP; Algazi A; Rizvi NA; Hoffner B; Mateus C; Gergich K; Lindia JA; Giannotti M; Li XN; Ebbinghaus S; Kang SP; Robert C
    JAMA; 2016 Apr; 315(15):1600-9. PubMed ID: 27092830
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pembrolizumab for the treatment of melanoma.
    Kumar SS; McNeil CM
    Expert Rev Clin Pharmacol; 2015; 8(5):515-27. PubMed ID: 26146011
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pembrolizumab for metastatic melanoma in a renal allograft recipient with subsequent graft rejection and treatment response failure: a case report.
    Kwatra V; Karanth NV; Priyadarshana K; Charakidis M
    J Med Case Rep; 2017 Mar; 11(1):73. PubMed ID: 28315636
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association of Vitiligo With Tumor Response in Patients With Metastatic Melanoma Treated With Pembrolizumab.
    Hua C; Boussemart L; Mateus C; Routier E; Boutros C; Cazenave H; Viollet R; Thomas M; Roy S; Benannoune N; Tomasic G; Soria JC; Champiat S; Texier M; Lanoy E; Robert C
    JAMA Dermatol; 2016 Jan; 152(1):45-51. PubMed ID: 26501224
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dermatologic toxicity from immune checkpoint blockade therapy with an interstitial granulomatous pattern.
    Trinidad C; Nelson KC; Glitza Oliva IC; Torres-Cabala CA; Nagarajan P; Tetzlaff MT; Ivan D; Hwu WJ; Prieto VG; Curry JL; Aung PP
    J Cutan Pathol; 2018 Jul; 45(7):504-507. PubMed ID: 29633300
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Not Available].
    Mateus C; Libenciuc C; Robert C
    Bull Cancer; 2016 Jun; 103(6 Suppl 1):S4-S11. PubMed ID: 27494973
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sarcoidosis-like syndrome and lymphadenopathy due to checkpoint inhibitors.
    Firwana B; Ravilla R; Raval M; Hutchins L; Mahmoud F
    J Oncol Pharm Pract; 2017 Dec; 23(8):620-624. PubMed ID: 27590328
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pembrolizumab for Treatment of Patients with Advanced or Unresectable Melanoma.
    Sullivan RJ; Flaherty KT
    Clin Cancer Res; 2015 Jul; 21(13):2892-7. PubMed ID: 25931451
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and efficacy of anti-PD-1 therapy for metastatic melanoma and non-small-cell lung cancer in patients with viral hepatitis: a case series.
    Kothapalli A; Khattak MA
    Melanoma Res; 2018 Apr; 28(2):155-158. PubMed ID: 29406396
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The safety of anti PD-1 therapeutics for the treatment of melanoma.
    Ramelyte E; Schindler SA; Dummer R
    Expert Opin Drug Saf; 2017 Jan; 16(1):41-53. PubMed ID: 27737598
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of anti-programmed cell death-1 immunotherapy for skin carcinomas and melanoma metastases in a patient with xeroderma pigmentosum.
    Salomon G; Maza A; Boulinguez S; Paul C; Lamant L; Tournier E; Mazereeuw-Hautier J; Meyer N
    Br J Dermatol; 2018 May; 178(5):1199-1203. PubMed ID: 29274233
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.